There are 3163 resources available
1972P - Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE
Presenter: Amanda Nizam
Session: Poster session 13
1973P - Urine-based molecular testing identifies FGFR alteration-positive patients for treatment with TAR-210
Presenter: Felix Guerrero-Ramos
Session: Poster session 13
1974P - A phase II trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder
Presenter: Guarionex DeCastro
Session: Poster session 13
1975P - Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100
Presenter: Petros Grivas
Session: Poster session 13
1978P - Accurate detection of urothelial carcinoma by whole-genome methylation profiling of urinary cell-free DNA
Presenter: Huiqin Guo
Session: Poster session 13
1979P - Disitamab vedotin (DV) plus toripalimab (T) in unresectable locally advanced or metastatic urothelial carcinoma (la/mUC): Long-term outcomes from a phase Ib/II study
Presenter: Li Zhou
Session: Poster session 13
1980P - Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial
Presenter: Evanguelos Xylinas
Session: Poster session 13
1981P - Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis
Presenter: Marco Stellato
Session: Poster session 13
1982P - Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)
Presenter: Begona Perez Valderrama
Session: Poster session 13